כל המחקרים
מורשהשלב I ושלב II (משולב) - מתן ראשון לבני אדםהתערבותי

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years

This research study, called ARO-DM1, is looking into a new medicine for people living with Type 1 Myotonic Dystrophy. We want to find out if this new medicine is safe for people to take and how well their bodies handle it. Researchers will also study how the medicine affects the disease. This first-stage study involves a small number of people and is focused on understanding side effects and proper dosing. Some participants will receive the new medicine, while others will receive a placebo – a harmless substance that looks like the medicine but has no active ingredients. Participants must be between 18 and 65 years old. This important step helps us learn if ARO-DM1 could be a helpful treatment in the future.

במבט חטוף

סטטוס
מורשה
שלב
שלב I ושלב II (משולב) - מתן ראשון לבני אדם
נותן חסות
Sarepta Therapeutics Inc.
יעד הרשמה
58
התחל
29 ינואר 2026

על מה המחקר הזה?

This study is about a new medicine, ARO-DM1, for people who have Type 1 Myotonic Dystrophy. Myotonic Dystrophy Type 1 is a genetic condition that causes muscles to become weak and waste away over time. It can affect many parts of the body.

The main goal of this particular study is to check if ARO-DM1 is safe for people to take. Researchers will be carefully looking for any side effects and how strong these side effects might be. They also want to understand how the medicine moves through the body and how the body gets rid of it. This helps them work out the best dose and how often it should be given. We hope this research will bring us closer to new treatments for this condition.

This is an early-stage study, meaning it's one of the first times this medicine is being tested in humans. It's an important step for new medicines to go through these stages to make sure they are safe and potentially effective before they can be used more widely.

נקודות עיקריות

  • This study is testing a new medicine (ARO-DM1) for Type 1 Myotonic Dystrophy.
  • המטרות העיקריות הן לבדוק את בטיחות התרופה וכיצד הגוף מתמודד איתה.
  • המשתתפים יקבלו או את התרופה החדשה או תרופת דמה (פלצבו).
  • It's an early-stage study, focused on understanding side effects and dosing.
  • You must be an adult, aged 18 to 65, to be considered for participation.

מי עשוי להיות זכאי?

This study is designed for adults. To take part, you need to be aged 18 years or older. There is no upper age limit listed, which means people older than 65 might also be considered, but the current range specified is up to 65 years.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. האם אתה בן 18 או יותר?
  2. Are you 65 years old or younger?
  3. Have you been diagnosed with Type 1 Myotonic Dystrophy?
  4. Are you able to attend regular appointments and follow study instructions?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to take part in this study, you will likely have several visits to a clinic or hospital. These visits will involve various checks, such as blood tests, physical examinations, and possibly tests to see how your muscles are working. You will receive either the study medicine, ARO-DM1, or a placebo (a dummy medicine) as an injection. Neither you nor the study team will know which you are receiving. The study involves regular follow-up appointments to monitor your health, any side effects, and how your body is responding to the treatment. The total length of your participation, including the treatment period and follow-up, will be decided by the study doctors.

סיכונים ותועלות פוטנציאליים

Taking part in a study like this might offer a chance to try a new treatment that isn't available yet, which could potentially help your condition. However, there are also risks, as the medicine is still being tested and could cause unexpected side effects. Some side effects might be uncomfortable or even serious. You will be closely monitored by doctors and nurses throughout the study. Remember, joining is always your choice, and you can withdraw from the study at any time, for any reason, without it affecting your usual medical care.

מיקומים (4)

חלק מהמיקומים באתר הם משוערים. אנחנו עובדים על שיפור זה — אנא ודאו עם צוות הניסוי לפני הנסיעה.
  • —
    לא מאומת
    ספרד
  • —
    לא מאומת
    גרמניה
  • —
    לא מאומת
    בלגיה
  • —
    לא מאומת
    איטליה

שאלות נפוצות

What is Type 1 Myotonic Dystrophy?

It's a genetic condition that causes muscles to weaken and waste away over time, affecting movement and other body functions.

מהו 'פלצבו'?

A placebo is a substance that looks exactly like the study medicine but doesn't contain any active ingredients. It helps researchers compare the effects of the new medicine.

What does 'dose-escalating' mean?

It means that different participants will receive different doses of the medicine, starting with small amounts and gradually increasing, so researchers can find the safest and most effective dose.

Why is this an 'early-stage' study?

This is one of the first times the medicine is being tested in people. It's focused on checking safety and how the body handles the medicine before it moves to larger studies.

האם אדע אם אני מקבל את התרופה האמיתית או את הפלצבו?

No, during the study, neither you nor the study team will know whether you are receiving the active medicine or the placebo. This is to ensure fair results.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.